Replies to post #97 on Equity Field Notes from temporal sources

[DanWebzster]

AMRN topline Reduce-It results are expected Q3/18

Next earnings release will be around May 2.

will have plenty of cash when Reduce-It is read out.

Vascepa YOY growth is slowing. 2018 may get a boost if Vascepa continues to get approval in the countries of the middle east

Reduce-It resuls will have a huge impact on the stock.